Kevin Balthaser Aclaris Therapeutics, Inc. (ACRS) insider trading activity

Kevin Balthaser is Chief Financial Officer of Aclaris Therapeutics, Inc.. Currently has a direct ownership of 160,413 shares of ACRS, which is worth approximately $404,240. The most recent transaction as insider was on Jan 02, 2026, when has been sold 4,461 shares (Common Stock) at a price of $2.88 per share, resulting in proceeds of $12,847. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 160K

73.22% 3M change

98.22% 12M change

Total Value Held $404,240

Kevin Balthaser Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2026	SELL Payment of exercise price or tax liability	$12,847 $2.88 p/Share	4,461 Reduced 2.71%	160,413 Common Stock
Jan 02 2026	BUY Exercise of conversion of derivative security	-	13,200 Added 7.41%	164,874 Common Stock
Jan 01 2026	SELL Payment of exercise price or tax liability	$6,772 $3.01 p/Share	2,250 Reduced 1.46%	151,674 Common Stock
Jan 01 2026	BUY Exercise of conversion of derivative security	-	7,500 Added 4.65%	153,924 Common Stock
Dec 31 2025	SELL Payment of exercise price or tax liability	$60,001 $3.01 p/Share	19,934 Reduced 11.98%	146,424 Common Stock
Dec 31 2025	BUY Exercise of conversion of derivative security	-	73,750 Added 30.72%	166,358 Common Stock
Mar 01 2025	SELL Payment of exercise price or tax liability	$1,446 $1.99 p/Share	727 Reduced 0.78%	92,608 Common Stock

Mar 01 2025	BUY Exercise of conversion of derivative security	-	3,475 Added 3.59%	93,335 Common Stock
Feb 01 2025	SELL Payment of exercise price or tax liability	$14,423 $2.48 p/Share	5,816 Reduced 6.08%	89,860 Common Stock
Feb 01 2025	BUY Exercise of conversion of derivative security	-	14,750 Added 13.36%	95,676 Common Stock
Jan 02 2025	SELL Payment of exercise price or tax liability	$12,546 $2.48 p/Share	5,059 Reduced 5.88%	80,926 Common Stock
Jan 02 2025	BUY Exercise of conversion of derivative security	-	13,200 Added 13.31%	85,985 Common Stock
Jan 01 2025	SELL Payment of exercise price or tax liability	$6,026 $2.48 p/Share	2,430 Reduced 3.23%	72,785 Common Stock
Jan 01 2025	BUY Exercise of conversion of derivative security	-	7,500 Added 9.07%	75,215 Common Stock
Dec 31 2024	SELL Payment of exercise price or tax liability	$76,215 $2.48 p/Share	30,732 Reduced 31.22%	67,715 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	-	73,750 Added 42.83%	98,447 Common Stock
Sep 01 2024	SELL Payment of exercise price or tax liability	$337 $1.18 p/Share	286 Reduced 1.14%	24,697 Common Stock
Sep 01 2024	BUY Exercise of conversion of derivative security	-	1,000 Added 3.85%	24,983 Common Stock
Mar 02 2024	SELL Payment of exercise price or tax liability	$529 $1.24 p/Share	427 Reduced 1.75%	23,983 Common Stock
Mar 02 2024	BUY Exercise of conversion of derivative security	-	1,500 Added 5.79%	24,410 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$1,227 $1.24 p/Share	990 Reduced 4.14%	22,910 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	-	3,475 Added 12.84%	23,587 Common Stock
Jan 01 2024	SELL Payment of exercise price or tax liability	$2,662 $1.05 p/Share	2,536 Reduced 11.04%	20,425 Common Stock
Jan 01 2024	BUY Exercise of conversion of derivative security	-	7,500 Added 24.62%	22,961 Common Stock
Sep 06 2023	BUY Open market or private purchase	$74,971 $7.9 p/Share	9,490 Added 38.03%	15,461 Common Stock

Kevin Balthaser

Chief Financial Officer

Wayne, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Value

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aclaris Therapeutics, Inc.

Track Activities on ACRS

Account